Latest news from University of Texas MD Anderson Cancer Center on News en-us Copyright 2024 News 115 31 / /images/newswise-logo-rss.gif /articles/healthy-women-have-cells-that-resemble-breast-cancer-study-finds/?sc=rsin /articles/healthy-women-have-cells-that-resemble-breast-cancer-study-finds/?sc=rsin Wed, 20 Nov 2024 11:00:00 EST A new study from researchers at The University of Texas MD Anderson Cancer Center finds that, in healthy women, some breast cells that otherwise appear normal may contain chromosome abnormalities typically associated with invasive breast cancer. The findings question conventional thinking on the genetic origins of breast cancer, which could influence early cancer detection methods. The study, published today in Nature, discovered that at least 3% of normal cells from breast tissue in 49 healthy women contain a gain or loss of chromosomes, a condition known as aneuploidy, and that they expand and accumulate with age. This poses questions for our understanding of "normal" tissues, according to principal investigator Nicholas Navin, Ph.D., chair of Systems Biology. University of Texas MD Anderson Cancer Center /articles/md-anderson-research-highlights-sitc-2024-special-edition/?sc=rsin /articles/md-anderson-research-highlights-sitc-2024-special-edition/?sc=rsin Sat, 09 Nov 2024 18:00:16 EST The University of Texas MD Anderson Cancer Center's Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson's world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. University of Texas MD Anderson Cancer Center /articles/md-anderson-launches-institute-for-cell-therapy-discovery-innovation-to-deliver-transformational-new-therapies/?sc=rsin /articles/md-anderson-launches-institute-for-cell-therapy-discovery-innovation-to-deliver-transformational-new-therapies/?sc=rsin Fri, 08 Nov 2024 12:00:57 EST The University of Texas MD Anderson Cancer Center today announced the launch of its Institute for Cell Therapy Discovery & Innovation, which will build upon longstanding MD Anderson clinical and research expertise to lead the world in developing and advancing impactful cell therapies for patients in need. University of Texas MD Anderson Cancer Center /articles/brown-foundation-award-for-excellence-in-oncology-nursing-honors-tiffany-richards/?sc=rsin /articles/brown-foundation-award-for-excellence-in-oncology-nursing-honors-tiffany-richards/?sc=rsin Wed, 06 Nov 2024 17:50:11 EST The University of Texas MD Anderson Cancer Center today honored Tiffany Richards, Ph.D., A.P.R.N., A.N.P.-B.C., A.O.C.N.P., with the 2024 Brown Foundation Award for Excellence in Oncology Nursing. University of Texas MD Anderson Cancer Center /articles/jennifer-bickel-m-d-named-md-anderson-vice-president-and-chief-wellness-officer/?sc=rsin /articles/jennifer-bickel-m-d-named-md-anderson-vice-president-and-chief-wellness-officer/?sc=rsin Fri, 01 Nov 2024 09:10:20 EST The University of Texas MD Anderson Cancer Center today announced the selection of Jennifer Bickel, M.D., as the institution's inaugural vice president and chief wellness officer (CWO). She will begin on January 6, 2025. Working closely with the senior vice president of people, culture and infrastructure, as well as the chief academic officer, she will spearhead initiatives that prioritize employee well-being, professional fulfillment and community resilience. University of Texas MD Anderson Cancer Center /articles/quitting-smoking-after-cancer-diagnosis-improves-survival-across-a-wide-variety-of-cancers/?sc=rsin /articles/quitting-smoking-after-cancer-diagnosis-improves-survival-across-a-wide-variety-of-cancers/?sc=rsin Thu, 31 Oct 2024 11:00:00 EST Smokers who are diagnosed with cancer now have more incentive to quit, as researchers from The University of Texas MD Anderson Cancer Center have found survival outcomes were optimized when patients quit smoking within six months of their diagnosis. University of Texas MD Anderson Cancer Center /articles/md-anderson-research-highlights-for-october-30-2024/?sc=rsin /articles/md-anderson-research-highlights-for-october-30-2024/?sc=rsin Wed, 30 Oct 2024 12:00:04 EST The University of Texas MD Anderson Cancer Center's Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson's world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. University of Texas MD Anderson Cancer Center /articles/combining-targeted-therapy-and-immunotherapy-improves-overall-survival-in-patients-with-anaplastic-thyroid-cancer/?sc=rsin /articles/combining-targeted-therapy-and-immunotherapy-improves-overall-survival-in-patients-with-anaplastic-thyroid-cancer/?sc=rsin Thu, 24 Oct 2024 11:00:00 EST Researchers from The University of Texas MD Anderson Cancer Center demonstrated that anti-PD-L1 immunotherapy in combination with mutation-directed targeted therapy extended overall survival (OS) in patients with anaplastic thyroid carcinoma (ATC). University of Texas MD Anderson Cancer Center /articles/md-anderson-expands-arts-experience-program-to-enhance-healing-and-well-being-for-patients/?sc=rsin /articles/md-anderson-expands-arts-experience-program-to-enhance-healing-and-well-being-for-patients/?sc=rsin Wed, 23 Oct 2024 14:00:01 EST As part of its ongoing commitment to patient comfort and healing, The University of Texas MD Anderson Cancer Center today announced a new focus on art to support the revitalization and expansion of its clinical facilities. This initiative will include the creation of a multisensory healing environment in both public spaces and patient care areas that are designed to prevent disease, promote health and foster well-being. University of Texas MD Anderson Cancer Center /articles/md-anderson-research-highlights-for-october-16-2024/?sc=rsin /articles/md-anderson-research-highlights-for-october-16-2024/?sc=rsin Wed, 16 Oct 2024 12:00:19 EST The University of Texas MD Anderson Cancer Center's Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson's world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. University of Texas MD Anderson Cancer Center /articles/allison-institute-scientific-symposium-features-spatial-biology-breakthroughs-5-million-gift-to-support-further-efforts/?sc=rsin /articles/allison-institute-scientific-symposium-features-spatial-biology-breakthroughs-5-million-gift-to-support-further-efforts/?sc=rsin Mon, 14 Oct 2024 17:20:39 EST The James P. Allison Institute at The University of Texas MD Anderson Cancer Center hosted its second annual scientific symposium on Oct. 10. The symposium, with more than 900 attendees, featured two Nobel laureates and a $5 million gift from the David and Eula Wintermann Foundation to advance the work of the Allison Institute. University of Texas MD Anderson Cancer Center /articles/dual-immunotherapy-plus-chemotherapy-benefits-specific-subset-of-patients-with-lung-cancer/?sc=rsin /articles/dual-immunotherapy-plus-chemotherapy-benefits-specific-subset-of-patients-with-lung-cancer/?sc=rsin Wed, 09 Oct 2024 11:00:00 EST Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that patients with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring specific mutations in the STK11 and/or KEAP1 tumor suppressor genes were more likely to benefit from adding the immunotherapy tremelimumab to a combination of durvalumab plus chemotherapy to overcome treatment resistance typically seen in this patient population. University of Texas MD Anderson Cancer Center /articles/md-anderson-and-uicc-collaborate-to-improve-women-s-cancer-care/?sc=rsin /articles/md-anderson-and-uicc-collaborate-to-improve-women-s-cancer-care/?sc=rsin Tue, 08 Oct 2024 09:05:00 EST The University of Texas MD Anderson Cancer Center today announced an agreement to become a Women's Cancer Partner with the Union for International Cancer Control (UICC), marking a significant collaboration to improve breast and cervical cancer care worldwide. University of Texas MD Anderson Cancer Center /articles/md-anderson-research-highlights-for-october-2-2024/?sc=rsin /articles/md-anderson-research-highlights-for-october-2-2024/?sc=rsin Wed, 02 Oct 2024 12:00:50 EST The University of Texas MD Anderson Cancer Center's Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson's world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. University of Texas MD Anderson Cancer Center /articles/md-anderson-research-highlights-special-edition-astro-2024/?sc=rsin /articles/md-anderson-research-highlights-special-edition-astro-2024/?sc=rsin Fri, 27 Sep 2024 18:05:06 EST This special edition features advances in radiation therapy approaches presented by MD Anderson researchers at the 2024 American Society for Radiation Oncology (ASTRO) Annual Meeting. Information on all MD Anderson ASTRO Annual Meeting content can be found at MDAnderson.org/ASTRO. University of Texas MD Anderson Cancer Center /articles/md-anderson-launches-first-ever-academic-journal-advances-in-cancer-education-quality-improvement/?sc=rsin /articles/md-anderson-launches-first-ever-academic-journal-advances-in-cancer-education-quality-improvement/?sc=rsin Fri, 27 Sep 2024 15:05:32 EST The University of Texas MD Anderson Cancer Center today announced its first-ever academic journal, Advances in Cancer Education & Quality Improvement (ACE-QI). The journal will publish research, training program summaries and quality improvement interventions for the oncology provider community. University of Texas MD Anderson Cancer Center /articles/michael-frumovitz-m-d-posthumously-honored-with-julie-and-ben-rogers-award-for-excellence/?sc=rsin /articles/michael-frumovitz-m-d-posthumously-honored-with-julie-and-ben-rogers-award-for-excellence/?sc=rsin Fri, 27 Sep 2024 11:05:00 EST The University of Texas MD Anderson Cancer Center has posthumously awarded Michael Frumovitz, M.D., with the Julie and Ben Rogers Award for Excellence in Patient Care. The annual award recognizes employees who consistently demonstrate excellence in their work and dedication to MD Anderson's mission to end cancer. University of Texas MD Anderson Cancer Center /articles/md-anderson-research-highlights-for-september-19-2024/?sc=rsin /articles/md-anderson-research-highlights-for-september-19-2024/?sc=rsin Thu, 19 Sep 2024 12:00:52 EST The University of Texas MD Anderson Cancer Center's Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson's world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. University of Texas MD Anderson Cancer Center /articles/novel-triplet-regimen-yields-promising-response-in-advanced-phase-chronic-myeloid-leukemia/?sc=rsin /articles/novel-triplet-regimen-yields-promising-response-in-advanced-phase-chronic-myeloid-leukemia/?sc=rsin Tue, 17 Sep 2024 18:30:00 EST According to researchers at The University of Texas MD Anderson Cancer Center, 80% of patients with previously untreated or relapsed/refractory advanced-phase chronic myeloid leukemia (CML) - including both accelerated or myeloid blast phases of the disease - or Philadelphia chromosome-positive acute myeloid leukemia (AML) achieved a bone marrow remission when treated with a novel combination of decitabine, venetoclax and ponatinib. University of Texas MD Anderson Cancer Center /articles/esmo-combination-therapy-reduced-agitated-delirium-in-patients-with-advanced-cancers/?sc=rsin /articles/esmo-combination-therapy-reduced-agitated-delirium-in-patients-with-advanced-cancers/?sc=rsin Sat, 14 Sep 2024 09:45:00 EST Treatment with a combination of haloperidol and lorazepam reduced symptoms of agitated delirium, a common end-of-life condition for patients with advanced cancers, compared with haloperidol alone, according to a new study led by researchers at The University of Texas MD Anderson Cancer Center. University of Texas MD Anderson Cancer Center